Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Liver International - Tập 35 Số 9 - Trang 2155-2166 - 2015
Joong‐Won Park1, Minshan Chen2, M. Colombo3, Lewis R. Roberts4, Myron Schwartz5, Pei‐Jer Chen6, Masatoshi Kudo7, Philip J. Johnson8, Samuel Wagner9, Lucinda Orsini10, Morris Sherman11
1Center for Liver Cancer, National Cancer Center, Goyang, KOREA
2Sun-Yat sen University Cancer Center, Guangzhou, China;
3Policlinic IRCCS Maggiore Hospital, University of Milan, Milan, Italy.
4Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA
5Mount Sinai Hospital, New York, NY. USA
6Taiwan National University, Taipei, Taiwan
7Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
8Birmingham University, Birmingham, UK
9Bristol-Myers Squibb, Princeton, NJ, USA.
10Bristol-Myers Squibb, Wallingford, CT, USA
11University of Toronto, Toronto, ON, Canada

Tóm tắt

AbstractBackground & Aims

Hepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC, from diagnosis to death.

Methods

Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions.

Results

Forty‐two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively (P < 0.0001).

Conclusions

Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.

Từ khóa


Tài liệu tham khảo

FerlayJ SoerjomataramI ErvikM et al.GLOBOCAN 2012 v1.0. Estimated cancer incidence mortality and prevalence worldwide. Available athttp://globocan.iarc.fr. Accessed 28 March 2014.

10.1016/j.jhep.2011.12.001

10.1016/S0140-6736(03)14964-1

10.1053/j.gastro.2011.12.061

10.1053/j.gastro.2007.04.061

10.1200/JCO.2008.20.7753

HowladerN NooneAM KrapchoM et al. (eds).SEER Cancer Statistics Review 1975‐2010 National Cancer Institute. Bethesda MD Available athttp://seer.cancer.gov/csr/1975_2010/ based on November 2012 SEER data submission posted to the SEER web site 2013. Accessed: 12 March 2015.

Dhanasekaran R, 2012, Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics, Hepat Med, 4, 19

10.1002/hep.24199

10.1038/ajg.2011.425

10.1111/j.1478-3231.2012.02838.x

Sloane D, 2006, Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival, J Natl Med Assoc, 98, 1934

10.1590/S1807-59322010001200010

10.1200/JCO.2010.28.7805

10.4137/CMO.S7633

10.1056/NEJMoa0708857

10.1016/S1470-2045(08)70285-7

10.1179/joc.2010.22.3.205

10.1634/theoncologist.2010-S4-42

ParkJ‐W ShermanM ColomboM et al.Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: first characterization of the full study population. Poster 4033. Presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1‐5 2012; Chicago Illinois.

10.1159/000111702

10.3350/kjhep.2009.15.3.391

10.1097/00000421-198212000-00014

10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W

10.1634/theoncologist.2010-S4-05

10.1016/j.idc.2010.07.004

10.1053/j.gastro.2004.09.011

Su FH, 2007, Forecasting the declining rate of chronic hepatitis‐B carrier status at a Taiwanese university: twenty years after implementation of an universal HBV vaccination program in Taiwan, Chang Gung Med J, 30, 521

10.1016/j.patbio.2009.11.002

10.1093/jjco/hye138

10.1093/jjco/hyn026

10.1093/jjco/hyq123

10.1159/000346220

10.1016/j.cgh.2011.03.027

10.1007/s12072-010-9165-7

10.1093/jnci/djn134

10.1111/j.1478-3231.2009.02166.x

10.1111/j.1440-1746.2011.06751.x

10.1111/j.1872-034X.2007.00216.x

WHO, 2011, Global Status Report on Alcohol and Health

Thông tin
Thông tin xuất bản

Liver International

Tập 35 Số 9

2155-2166

Thông tin tác giả